Search

New medications for metastatic breast cancer (MBC) can be of great benefit to patients, but these medicines also increase expenditures. Cost-utility analyses (CUAs) are needed to allocate health resources properly, and health utility values are required to calculate quality-adjusted life years in those CUAs. This study aimed to measure health utility values for several MBC-related health states and certain breast cancer treatment-related grade 3/4 adverse drug reactions (ADRs). [Extracted from the article]

Treatment options for HER-2-positive metastatic breast cancer (mBC) patients have expanded markedly since trastuzumab approval in 1998. This study assesses the cost-effectiveness of four treatment sequences for HER-2-positive mBC according to the Taiwanese National Health Insurance Administration (TNHIA). Methods Lifetime costs (U.S. Dollars) and effectiveness (quality-adjusted life years) of treatment decisions for HER-2-positive mBC patients were examined using a Markov model. [Extracted from the article]